gentaur.com

Novel Reagent Using Spectrophotometry

Sensitive detection of iron (II) sulfate with a novel reagent using spectrophotometry

In this study, a novel reagent was developed for sensitive detection of iron (II) sulfate, spectrophotometrically. A novel thio-anthraquinone derivative, 1-(Dodecylthio)anthracene-9,10-dione (3), was synthesized from the chemical reaction of 1-Chloroanthraquinone (1) and 1-Dodecanethiol (2) by an original reaction method and was used in the preparation of the novel reagent called Catal’s reagent.
  • A synthesized thio-anthraquinone analogue (3) was purified by column chromatography, and its chemical structure was characterized by spectroscopic methods such as Fourier-transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and ultraviolet (UV)-visible spectrophotometry.
  • The chemical and molecular structure of the developed thio-antraquinone derivative (3) was illuminated using computational methods with the GaussView5 and Gaussian09 programs. Various solvents including ethanol, methanol, and acetonitrile were examined in the preparation of the reagent. A concentration range from 0.2 mg mL-1 up to 10 mg mL-1 of iron (II) sulfate heptahydrate solution in distilled water was prepared. The absorption spectra of Catal’s reagent (0.816 mM) showed three peaks between 185 nm-700 nm of wavelength.
  • However, after the reaction with H2O2 and the 30 mM trisodium citrate dihydrate mixture in the presence of an iron sulfate (II) solution, a single peak was observed, producing a stable and reddish/brownish homogenous solution (λ max = 304 nm).
  • The following concentrations of iron (II) sulfate heptahydrate was examined using developed protocol and the reagent, and the concentrations were measured spectrophotometrically at 304 nm, 0.2-1 mg mL-1. Absorbances of reaction mixtures of iron (II) sulfate remained stable up to 48 h.
  • The results indicated that the novel Catal’s reagent can be used for sensitive spectrophotometric detection of iron (II) sulfate in aqueous solutions.
gentaur.com

gentaur

CD103 / CD22 / CD20 Antibody (FITC, PE, PerCP)
abx200637-50tests 50 tests
EUR 773

NATtrol Zika Virus Stock (Qualitative) (1 mL)
TEST 1 mL
EUR 1106.64
Description: Please contact Gentaur in order to receive the datasheet of the product.

B-Lymphocyte Antigen CD20 (CD20) Antibody (RPE)
abx413280-100tests 100 tests
EUR 592

B-Lymphocyte Antigen CD20 (CD20) Antibody (RPE)
abx413281-25tests 25 tests
EUR 314

human CD20/MS4A1 linear peptide (165-184, 20-aa, extracellular domain) broad reactivity with CD20-specific antibodies
CD20-165-P 100 ug
EUR 225

B-Lymphocyte Antigen CD20 (CD20) Antibody (PE)
abx133981-100Assays 100 Assays
EUR 495

B-Lymphocyte Antigen CD20 (CD20) Antibody (PE)
abx133981-50Assays 50 Assays
EUR 398

B-Lymphocyte Antigen CD20 (CD20) Antibody (PE)
abx200174-100tests 100 tests
EUR 453

B-Lymphocyte Antigen CD20 (CD20) Antibody (PE)
abx139197-100tests 100 tests
EUR 481

CD20 antibody (PE-CY7)
61R-CD20bHUPEC7 100 tests
EUR 446
Description: Mouse monoclonal CD20 antibody (PE-CY7)

Anti-Hu CD20 PE
1P-638-T025 25 tests
EUR 140

Anti-Hu CD20 PE
1P-638-T100 100 tests
EUR 240

CD20 antibody (FITC)
61R-CD20bHUFT 100 tests
EUR 273
Description: Mouse monoclonal CD20 antibody (FITC)

CD20 Antibody (FITC)
abx139195-100tests 100 tests
EUR 425

CD20 Antibody (FITC)
abx139196-100tests 100 tests
EUR 425

anti- SR-BI antibody
FNab08215 100µg
EUR 548.75
Description: Antibody raised against SR-BI

EZ-DNA Reagents
BS8202 100preps
EUR 88.06

EZ-DNA Reagents
SK8201 100preps
EUR 93.5

B-Lymphocyte Antigen CD20 (CD20) Antibody (PE-Cy5)
abx133982-100Assays 100 Assays
EUR 495

B-Lymphocyte Antigen CD20 (CD20) Antibody (PE-Cy5)
abx133982-50Assays 50 Assays
EUR 398

Humanized (chimeric) Anti-Human CD20/MS4A1 IgG (rituximab biosimilar), pure
CD20-23-M 100 ul
EUR 482

B-Lymphocyte Antigen CD20 (CD20) Antibody (FITC)
abx413278-01mg 0.1 mg
EUR 509

Anti-Hu CD20 PE-DyLight594
T5-638-T025 25 tests
EUR 154

Anti-Hu CD20 PE-DyLight594
T5-638-T100 100 tests
EUR 268

Anti-Hu CD20 PE-Cy7
T7-638-T025 25 tests
EUR 154

Anti-Hu CD20 PE-Cy7
T7-638-T100 100 tests
EUR 268

Anti-Hu CD20 PE-Cy5
T8-638-T025 25 tests
EUR 140

Anti-Hu CD20 PE-Cy5
T8-638-T100 100 tests
EUR 240

Human CD20/MS4A1 control/blocking peptide (EC-domain, rituximab binding domain)
CD20-22-P 100 ug
EUR 164

Anti-Hu CD20 FITC
1F-414-T025 25 tests
EUR 122

Anti-Hu CD20 FITC
1F-414-T100 100 tests
EUR 204

Anti-Hu CD20 FITC
1F-638-T025 25 tests
EUR 122

Anti-Hu CD20 FITC
1F-638-T100 100 tests
EUR 204

B-Lymphocyte Antigen CD20 (CD20) Antibody (PE-DyLight 594)
abx139199-100tests 100 tests
EUR 523

Recombinant (HEK cells) human CD20/MS4A1 (141-184 aa) hFc- fusion Protein
CD20-146-R 10 ug
EUR 408

Recombinant (HEK cells) purified human CD20/MS4A1 (213-297 aa) His-tag Protein
CD20-145-R 20 ug
EUR 408

Recombinant (HEK cells) purified Ferrret CD20/MS4A1 (213-297 aa) His-tag Protein
CD20-147-R 10 ug
EUR 408

Rabbit Anti-Human CD20/MS4A1 peptide (EC-domain, rituximab binding domain) IgG, aff pure
CD20-22-A 100 ul
EUR 482

CD20/MS4A1 linear peptide (QDKLTQWPKWLEg, 13-aa) contains WPXWLE motif and reacts with rituximab
CD20-RP5L-P 100 ug
EUR 164

anti- CD20 antibody
FNab01440 100µg
EUR 585
Description: Antibody raised against CD20

anti- CD20 antibody
FNab01441 100µg
EUR 548.75
Description: Antibody raised against CD20

BI 6727
2222-1
EUR 120

BI 6727
2222-5
EUR 327

BI-2536
2370-25
EUR 523

BI-2536
2370-5
EUR 175

BI-D1870
1924-1
EUR 142

BI-D1870
1924-5
EUR 370

BI-78D3
B1686-25
EUR 528

BI-78D3
B1686-5
EUR 175

BI-7273
B1879-25
EUR 892

BI-7273
B1879-5
EUR 262

BI-9564
B1880-25
EUR 756

BI-9564
B1880-5
EUR 229

BI-409306
B2377-25
EUR 756

BI-409306
B2377-5
EUR 229

BI-7273
HY-100351 50mg
EUR 877

BI-9564
HY-100352 200mg
EUR 2254

BI 689648
HY-101217 25mg
EUR 2116

BI-78D3
HY-10366 25mg
EUR 349

BI-6C9
HY-103661 50mg
EUR 1083

BI-D1870
HY-10510 2mg
EUR 147

BI-882370
HY-107779 100mg
EUR 1164

BI-3802
HY-108705 10mg
EUR 911

BI-3812
HY-111381 25mg
EUR 1772

BI-3663
HY-111546 1mg
EUR 681

BI-749327
HY-111925 100mg
EUR 3092

BI-409306
HY-112831 50mg
EUR 2058

BI-671800
HY-114141 100mg
EUR 3092

BI-1347
HY-120350 10mM/1mL
EUR 176

BI-167107
HY-121251 100mg
EUR 2633

BI-4464
HY-124625 10mg
EUR 911

BI 01383298
HY-124738 10mM/1mL
EUR 163

BI-4020
HY-129550 10mg
EUR 681

BI-9627
HY-18071 5mg
EUR 291

BI 224436
HY-18595 5mg
EUR 533

(±)-BI-D
HY-18601 100mg
EUR 2943

BI-847325
HY-18955 100mg
EUR 1262

BI 2536
HY-50698 100mg
EUR 1229

BI-D1870
B2227-10 10 mg
EUR 270
Description: BI-D1870 is a cell-permeable inhibitor of the p90 RSK isoforms with IC50 values of 31nM, 24nM, 18nM and 15nM for RSK1, RSK2, RSK3 and RSK4 respectively [1].BI-D1870 is a derivative of dihydropteridinone and found to be a remarkably specific inhibitor of RSK isoforms.

BI-D1870
B2227-5 5 mg
EUR 189
Description: BI-D1870 is a cell-permeable inhibitor of the p90 RSK isoforms with IC50 values of 31nM, 24nM, 18nM and 15nM for RSK1, RSK2, RSK3 and RSK4 respectively [1].BI-D1870 is a derivative of dihydropteridinone and found to be a remarkably specific inhibitor of RSK isoforms.

BI-D1870
B2227-5.1 10 mM (in 1mL DMSO)
EUR 235
Description: BI-D1870 is a cell-permeable inhibitor of the p90 RSK isoforms with IC50 values of 31nM, 24nM, 18nM and 15nM for RSK1, RSK2, RSK3 and RSK4 respectively [1].BI-D1870 is a derivative of dihydropteridinone and found to be a remarkably specific inhibitor of RSK isoforms.

BI-D1870
B2227-50 50 mg
EUR 595
Description: BI-D1870 is a cell-permeable inhibitor of the p90 RSK isoforms with IC50 values of 31nM, 24nM, 18nM and 15nM for RSK1, RSK2, RSK3 and RSK4 respectively [1].BI-D1870 is a derivative of dihydropteridinone and found to be a remarkably specific inhibitor of RSK isoforms.

BI 6015
B5668-10 10 mg
EUR 179
Description: BI 6015 is an antagonist of hepatocyte nuclear factor 4? [1]. Hepatocyte nuclear factor 4? (HNF4?) is a nuclear receptor and regulates gene expression in enterocytes, hepatocytes and pancreatic ? cells [1]. BI 6015 is a HNF4? antagonist.

BI 6015
B5668-5 5 mg
EUR 118
Description: BI 6015 is an antagonist of hepatocyte nuclear factor 4? [1]. Hepatocyte nuclear factor 4? (HNF4?) is a nuclear receptor and regulates gene expression in enterocytes, hepatocytes and pancreatic ? cells [1]. BI 6015 is a HNF4? antagonist.

BI 6015
B5668-50 50 mg
EUR 595
Description: BI 6015 is an antagonist of hepatocyte nuclear factor 4? [1]. Hepatocyte nuclear factor 4? (HNF4?) is a nuclear receptor and regulates gene expression in enterocytes, hepatocytes and pancreatic ? cells [1]. BI 6015 is a HNF4? antagonist.

BI-847325
B6014-1 1 mg
EUR 132
Description: BI 847325 is a dual inhibitor of Ras-mitogen-activated protein kinase kinases (MEK) and Aurora kinases [1,2]. BI 847325 inhibits MEK1 and MEK2 with IC50 values of 25 and 4 nM, respectively.

BI-847325
B6014-5 5 mg
EUR 242
Description: BI 847325 is a dual inhibitor of Ras-mitogen-activated protein kinase kinases (MEK) and Aurora kinases [1,2]. BI 847325 inhibits MEK1 and MEK2 with IC50 values of 25 and 4 nM, respectively.

BI-9564
B6184-1 1 mg
EUR 109
Description: IC50: 75 nM and 3.4 ?M for BRD9 and BRD7 bromodomains, respectivelyBI-9564 is a BRD9/7 specific inhibitor.BRD7 and BRD9 are two important members of the bromodomain family protein.

BI-9564
B6184-10 10 mg
EUR 293
Description: IC50: 75 nM and 3.4 ?M for BRD9 and BRD7 bromodomains, respectivelyBI-9564 is a BRD9/7 specific inhibitor.BRD7 and BRD9 are two important members of the bromodomain family protein.

 

Engineering caspase 7 as an affinity reagent to capture proteolytic products

Many proteases recognize their substrates with high specificities, with this in mind, it should theoretically be possible to utilize the substrate binding cleft of a protease as a scaffold to engineer an affinity reagent. In this study, we sought to develop reagents that would differentiate between substrates and products of proteolysis, based on a caspase 7 scaffold. Firstly, we engineered a form of caspase 7 that can undergo conversion to a substrate binding conformation without catalysis. Seeking to generate a product-only trap, we further engineered this construct by incorporating mutations that compensate for the generation of a negative charge in the neo C terminus of a newly generated product.
  • This was accomplished with only three substitutions within the substrate binding cleft. Moreover, the affinity of the product trap for peptides was comparable to the affinity of caspase 7 to parental substrates.
  • Finally, generation of a hybrid fluorescent protein with the product trap provided a reagent that specifically recognized apoptotic cells and highlights the versatility of such an approach in developing affinity and imaging agents for a variety of cysteine and serine proteases.

Leveraging nature’s biomolecular designs in next-generation protein sequencing reagent development

Next-generation approaches for protein sequencing are now emerging that could have the potential to revolutionize the field in proteomics. One such sequencing method involves fluorescence-based imaging of immobilized peptides in which the N-terminal amino acid of a polypeptide is readout sequentially by a series of fluorescently labeled biomolecules.

When selectively bound to a specific N-terminal amino acid, the NAAB (N-terminal amino acid binder) affinity reagent identifies the amino acid through its associated fluorescence tag. A key technical challenge in implementing this fluoro-sequencing approach is the need to develop NAAB affinity reagents with the high affinity and selectivity for specific N-terminal amino acids required for this biotechnology application.

One approach to develop such a NAAB affinity reagent is to leverage naturally occurring biomolecules that bind amino acids and/or peptides. Here, we describe several candidate biomolecules that could be considered for this purpose and discuss the potential for developability of each.

Key points • Next-generation sequencing methods are emerging that could revolutionize proteomics. • Sequential readout of N-terminal amino acids by fluorescent-tagged affinity reagents. • Native peptide/amino acid binders can be engineered into affinity reagents. • Protein size and structure contribute to feasibility of reagent developability.

Product not found